Gabon Ibogaine Collective
About the Collective

About

Gabon Ibogaine Collective is an independent information resource on ibogaine for people researching ibogaine. Our work focuses on evidence, safety, legality and practical questions; this page explains who we are, how we curate content, and what readers can expect.

Independent, evidence-first Plain language resources

Our editorial approach

We focus on clarity and traceability. Content is written to explain how and why information is included rather than to promote treatments or services.

We compile and contextualize primary sources — peer-reviewed literature, official registries, and regulatory texts — then summarise findings with clear attributions. Where readers seek practical pathways, we link to external resources that document clinical programs and firsthand accounts; for example, some readers compare regional programs such as those described by the ibogaine treatment network in Texas (ibogaine treatment in Texas) or providers operating in Mexico (ibogaine treatment centers in Mexico), which we cite when relevant.

We also note distinctions between information types: research summaries, legal summaries, and anecdotal reports are labeled so readers can judge reliability quickly.

How information is sourced and vetted

We prioritise primary, verifiable sources and transparent methodology. When summarising evidence we check the original publication or official registry, tag the date of last review, and flag areas where evidence is sparse or contested.

To support that process we consult established reference sources such as the National Library of Medicine's PubMed summaries (https://pubmed.ncbi.nlm.nih.gov/) for literature indexing and general context like encyclopedia overviews on Wikipedia's Ibogaine entry for widely cited historical notes. For regulatory context we reference authoritative policy pages such as the U.S. Drug Enforcement Administration's listings when discussing classifications (DEA).

We avoid original clinical claims. When content touches on treatment pathways or experimental uses, we make clear the limits of evidence and link to primary trial registries or institutional pages rather than offering endorsements; for example, readers curious about clinical research sometimes review materials like summaries of experimental Parkinson's research that have been discussed publicly (ibogaine treatment for Parkinson's), which we reference only to document public reporting.

Contextual scene relating to ibogaine practice in Gabon

Editorial principles

Our principles guide what we publish and how we present it.

  • Independence: No commercial affiliations influence editorial choices.
  • Plain language: Complex evidence is translated into clear summaries for readers researching ibogaine.
  • Evidence-first: Claims are supported by primary sources or clearly marked as anecdote.
  • Transparency: Sources and limits are disclosed; we document review dates.
  • Respect: Cultural contexts and conservation concerns are treated with care.

Who this is for

This resource is for people researching ibogaine and those seeking to understand safety, law, and practical questions relevant to the topic. It is not intended as a substitute for professional medical or legal advice.

If you are exploring treatment options, compare our editorial summaries with clinic or program information from provider pages such as those in Mexico (ibogaine treatment centers in Mexico) and curated review sites like NewPath reviews, while keeping in mind the editorial distinction between description and endorsement.

For guidance on how to use our site, the homepage provides entry points to our sections and topical pages; see the overview available via our site index at the main navigation.